| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| QSAM Biosciences, Inc. | Director | Common Stock | 2,883,943 | $8,651,829 | $3.00 | 06 Dec 2021 | Direct |
| QSAM Biosciences, Inc. | Director | Options to buy common | 55,000 | 24 Aug 2021 | Direct | ||
| SAB Biotherapeutics, Inc. | Director | Stock Option (right to buy) | 9,305 | 15 Jul 2024 | Direct | ||
| QSAM Biosciences, Inc. | Director | Series E-1 Preferred Shares | 0 | 15 Feb 2021 | Direct | ||
| QSAM Biosciences, Inc. | Director | Series E-1 Preferred Stock | 0 | 06 Dec 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| SABS | SAB Biotherapeutics, Inc. | 15 Jul 2024 | 2 | $0 | 4 | Director | 17 Jul 2024, 16:30 |
| SABS | SAB Biotherapeutics, Inc. | 07 Dec 2022 | 2 | +$49,999 | 4 | Director | 09 Dec 2022, 08:01 |
| /report/000149315222004626-link-david-charles-2021-12-31 | QSAM Biosciences, Inc. | 31 Dec 2021 | 4 | $0 | 5 | Director | 15 Feb 2022, 05:11 |
| SABS | SAB Biotherapeutics, Inc. | 22 Oct 2021 | 7 | $0 | 4 | Director | 26 Oct 2021, 21:49 |
| SABS | Big Cypress Acquisition Corp. | 22 Oct 2021 | 0 | $0 | 3 | Director | 22 Oct 2021, 21:24 |